NuGenerex Immuno-Oncology, Inc.

Share · US67053X1028 (OTC)

No Price

n/a

Company Profile for NuGenerex Immuno-Oncology, Inc. Share

NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.

AI Analysis of NuGenerex Immuno-Oncology, Inc.

Click any analysis below to get instant AI insights from finAgent

Latest AI Analyses of NuGenerex Immuno-Oncology, Inc.

No AI threads available for this company yet.

Company Data

Name NuGenerex Immuno-Oncology, Inc.

Company NuGenerex Immuno-Oncology, Inc.

Website https://www.generex.com/nugenerex-family-of-companies

Primary Exchange

UTC

ISIN US67053X1028

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Joseph Moscato

Country United States of America

Currency USD

Employees 0,0 T

Address 10102 USA Today Way, 33025 Miramar

IPO Date 2021-03-15

Ticker Symbols

Name	Symbol
Over The Counter	NUGX

More Shares

Investors who hold NuGenerex Immuno-Oncology, Inc. also have the following shares in their portfolio:

BL.PRIV.CR.F 24/29 REGS Bond

Federated Hermes Kaufmann Small Cap A Fund

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog